Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia
Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro M. Gianni(University of Milan), Stefano Buttiglieri(University of Turin), Carmelo Carlo‐Stella(Humanitas University), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Silvia L. Locatelli(Humanitas University), Corrado Tarella(A. O. Ordine Mauriziano di Torino), Arianna Giacomini(University of Brescia), Massimo Di Nicola(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Marco Ruella(Parker Institute for Cancer Immunotherapy), M. Testi, Luigi Mariani(University of Mataram), Alessandra Risso(University of Turin)
Cited by 28
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience
|Liver Transplantation|2011|580
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308